Downgrades Buy Neutral X

VRAY ViewRay

B. Riley Securities

$4 $1

Downgrades Buy Hold X

VRAY ViewRay

Jefferies

$7 $1.25

Downgrades Buy Neutral X

VRAY ViewRay

BTIG Research

Downgrades Outperform Perform X

VRAY ViewRay

Oppenheimer

Downgrades Buy Hold X

VRAY ViewRay

Stifel

$7 $1.75

Initiated Buy X

VRAY ViewRay

Stifel

$7

Upgrades Neutral Buy X

VRAY ViewRay

B. Riley Securities

$7

Resumed Neutral X

VRAY ViewRay

B. Riley Securities

$7

Upgrades Neutral Buy X

VRAY ViewRay

Guggenheim

$7

Upgrades Neutral Buy X

VRAY ViewRay

BTIG Research

$7

Initiated Overweight X

VRAY ViewRay

Piper Jaffray

$15

Reiterated Buy X

VRAY ViewRay

B. Riley FBR

$13.75 $12

Initiated Equal-Weight X

VRAY ViewRay

Morgan Stanley

$7

Initiated Outperform X

VRAY ViewRay

Robert W. Baird

Initiated Buy X

VRAY ViewRay

Jefferies

Initiated Buy X

VRAY ViewRay

B. Riley FBR, Inc.

$13.50

VRAY  ViewRay, Inc.

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.